Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus Gemcitabine in Advanced Pancreatic Cancer
NCT00028834Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2002
- Primary completion
- Dec 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in pancreatic adenocarcinoma (PDAC), sponsored by National Cancer Institute. Started Feb 2002; status: completed.
02
Drugs
bevacizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00028834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00028834.